Home                                                               PLEASE LETS REMEMBER THE 96 LIVERPOOL FC FANS WHO DIED WATCHING THEIR TEAM 25 YEARS AGO

About Us
Contact Us
Our Committee
Our President
Thalidomide Q&A
Our Campaigns
Video Library
Our Disability
Thalidomide World Links
News Review
The Drugs Uses
World of Thalidomide
Legal Challange 2012
Thalidomide Brands
Compensation Info
Animal Testing
Dangerous Medicines
Diageo Agreement
How to Claim
Voting Online
Freddie Musena Tribute
Medical Info
Website Rules
Thalidomide Trust
under construction 5
under construction 6
under construction 7
under construction 8




 This website is dedicated to the history of the drug 'thalidomide' and we explore the various disabilities that the drug caused to babies worldwide.

 Since Thalidomide UK was founded in 1993, against all odds, Diageo have put additional monies into the trust on three separate occasions. Payments are being made to provide some facilities (adaptation of properties/wheelchairs/cars, etc) to alleviate the problems.

 The thalidomide disabilities was a man-made by a drug, which could have been so easily avoided if the manufactures and suppliers had carried out the adequate testing on the drug. Those who were responsible for the marketing of the drug did not have a care for human life.


Freddie Astbury - PRESIDENT
(Medicines 'Teratogenic' Regulatory Consultant)


Freddie Astbury

President/Founder/Head Consultant of Thalidomide UK

Thalidomide Agency UK website provides information the use of thalidomide and similar drugs. 

 In 1985 when the world discovered that the drug thalidomide was being used in the treatment of leprosy and that babies were still being born in countries like Brazil, our immediate response was to call for the drug to be banned.

 Over the years, most thalidomiders have come to accept that if it can help people who suffer from number of illnesses then it must be used but only under the strictest guidelines such as a risk Management Programme.

 In our ideal world, thalidomide would be banned, but we have to accept that we live in the real world. We believe that the best way forward is to work on Risk Management Programme like the European Pregnancy Prevention

Programme and the STEPS Programme in the USA, with the manufactures and suppliers that would reduce the chances of more babies being damaged by the drug.


What Is Thalidomide?

 The drug ‘Thalidomide’ was mainly prescribed to pregnant women for morning sickness in the late 50s and early 60s. Instead, the drug caused severe deformities in babies with missing limbs.

Some thalidomide people where also born with internal deformities. It is estimated that over 3,500 babies died before their first birthday. Thalidomide was invented in 1954 at the Grünenthal Labs in Germany by the inventors Dr. W. Kunz (chemical synthesis) and Dr. H. Keller pharmacological description of sedative properties).





 Thalidomide UK Website Symbol 2009




Accutane or Roaccutane

(generic name isotretinoin)

Hundreds of drugs still pose the risk of birth abnormalities. It is a retinoid, meaning it derives from vitamin A and is found in small quantities naturally in the body.

 Accutane, or Roaccutane (generic name isotretinoin) Amnesteem are members of a family of drugs called retinoids which are known to cause a number of very serious birth defects, and has been implicated as a possible cause of cleft lip and cleft palate. Isotretinoin is derived from vitamin A.

 Oral isotretinoin is marketed under various trade names, most commonly Accutane (Roche), Amnesteem (Mylan), Claravis (Barr), Decutan (Actavis), Isotane (Pacific Pharmaceuticals), Sotret (Ranbaxy), Oratane (Genepharm Australasia) or Roaccutane (Roche), Izotek (BlauFarma); while topical isotretinoin is most commonly marketed under the trade names Isotrex or Isotrexin (Stiefel).

 What is even more terrifying is that the drugs are aimed at teenagers for the treatment of ACNE.

 Accutane and Roaccutane This drug is NOT manufactured by Celgene the suppliers of Thalidomide or Revlimid, but the pharmaceutical giants Roche.

 Celgene, however is the owner of the business process patents on components which will be essential elements of the new isotretinoin RiskMAP. Celgene is not involved in the strengthened isotretinoin RiskMAP aside from the patent negotiations.

In US the U.S. Food and Drug Administration 'FDA or USFDA' (an agency of the United States Department of Health and Human Services and is responsible for regulating and supervising the safety of foods, dietary supplements, drugs, vaccines, biological medical products, blood products, medical devices, radiation-emitting devices, veterinary products, and cosmetics) has insisted that the drug has a stronger Risk Management Programme than used in the past.

 The new Risk Management Programme is called iPLEDGE.

The iPLEDGE program is a mandatory distribution program in the United States for isotretinoin (commonly sold under the trade names Accutane, Amnesteem, Claravis or Sotret), intended to prevent the use of the drug during pregnancy due to the high risk of birth defects.


Thalidomide UK radio

launches in MAY 2014

View thalidomide radio website (new)

(Please click on the PHOTO above to view the

Thalidomide Radio Website NEW)


  Thalidomide Radio Commercial 2014

(Please click on the button above to listen to our commercial)

thalidomide radio information

thalidomide radio will be available in all countries via the websiteThalidomide. You will be able to listen to our new station in various ways i.e.:

Thalidomide Radio website (website launch January 2014) or Thalidomide Radio Facebook (a public social network site).

Thalidomide Radio will make sure that news, conversation and interviews on thalidomide and other similar type medicines is our priority. We however will be introducing Music and Comedy programs into our Line-up.

Our aim is to educate the younger generation into the History of Thalidomide and therefore feel that it is in the interest of our people to make sure that they listen to the New Radio Station.

If you have any ideas for the New Radio Station then please e-mail: or even if you want to be in interviewee please let us know by the same method.

Early access drugs scheme launched for severely ill

Severely ill patients and those with rare debilitating conditions could be given new medicines years before they are licensed, under new regulations.

The Early Access to Medicines scheme would enable a small number of promising medicines to be fast-tracked.

The idea is to help patients in England with severe illnesses who have no other treatment options.

The Medicines and Healthcare Products Regulatory Agency (MHRA) will oversee the scheme, being launched in April.

Health Secretary Jeremy Hunt said: "What patients want is sometimes to try medicines that may not be clinically proven to be effective but are clinically safe.

"We are streamlining the process so these medicines can be used much earlier - particularly if they have early promise - and that is something which will bring hope to a lot of patients."

Source BBC

Freddie Astbury President of Thalidomide UK said: this is very good news for terminally ill patients, who have tried all medicines and it were desperate to get treatment that could prolonged life or in even in a small number of cases would cure their diseases.

People must remember that unfortunately in many cases this can often be life threatening disease and that they have no alternative but to try new medicines. We are sure, after working with the MHRA that they have taken all  necessary precautions in making sure that these medicines are safe.

Diageo reaches settlement with the Australian and New Zealand thalidomide SURVIVORS

Drinks giant Diageo has been praised for its compassion after agreeing a £49 million settlement with more than 100 thalidomide victims in Australia and New Zealand.

Lawyer Peter Gordon told the Victoria state Supreme Court the deal, subject to court approval, brought to an end a long battle for compensation and praised the global firm’s constructive approach.

The drug was given to pregnant women in the 1950s and 1960s as a treatment for morning sickness, but was pulled from the market in 1961 after it was linked to birth defects.

Diageo was not itself responsible for the distribution or sale of the drug.

However the Distillers Company, which distributed it in Australia, was bought by Guinness in 1986, ahead of the creation of Diageo 11 years later.

3 December 2013


morning sickness drug thalidomide: 23 Spanish SURVIVORS where awarded compensation

Spanishthe victims of the morning sickness drug Thalidomide said they have been awarded compensation after fighting against a pharmaceutical company for decades.

The court has recognized 23 victims, who will receive a minimum of $807,900 from the company, Grünenthal, The chairman of the Thalidomide victims' association, AVITE, said the verdict is historic. "We have regained some of the dignity which we should never have had to have lost, but which we lost before we were born," Chairman Jose Riquelme said. Thalidomide, first prescribed in 1957 as a morning sickness drug, caused a range of deformities in the infants, including missing fingers, elbows and knees.

Thousands of babies were affected, and many victims had to undergo amputations as a result of the deformities. Although only 23 victims were awarded compensation, those who feel they have a valid claim should attend court for a medical examination to certify their condition.

Thursday 21st November, 2013


Speech on the occasion of the inauguration of Thalidomide-Memorial

Translation of the German speech by Harald F. Stock, PhD., Chief Executive Officer of the Grünenthal Group, on the occasion of the Thalidomide-Memorial inauguration upon invitation by the City of Stolberg on 31st August 2012 in Stolberg/Rhineland

In numerous talks with those affected, but also for example with the Ministry of Health, Equalities, Care and Ageing of North Rhine-Westphalia – especially in the last few months, we learned how much it is publicly desired that we express our deep regrets to those affected by Thalidomide, and in particular to their mothers.

We are aware of our responsibility and will continue to fulfil it in demand-oriented projects and initiatives.

The fact that I can stand here today and address a few words to you is nevertheless not a matter of course.

We also apologize for the fact that we have not found the way to you from person to person for almost 50 years. Instead, we have been silent and we are very sorry for that.

We ask that you regard our long silence as a sign of the silent shock that your fate has caused us. We have learned how important it is that we engage in an open dialogue with those affected and to talk and to listen to them. We have begun to mutually develop and implement projects with them, to improve their living situation and assist in hardship situations easily and efficiently. We will continue to pursue this path in the future.

Grunenthal Full Statement Apology

Freddie Astbury (President) Official Statement

 We have studied Grünenthal’s speech made by Harald Stock and recognise words that Grunenthal have apologised for the fact that they have not found the way to you from person to person for almost 50 years. Instead, they have been silent and we are very sorry for that.

We also acknowledge that they have begun to mutually develop and implement projects with them, to improve their living situation and assist in hardship situations easily and efficiently. We will continue to pursue this path in the future.

There are currently 469 registered thalidomide survivors UK through who desperately needs help in making their lives easier as their health has deteriorated dramatically over last number of years and sadly thalidomide survivors will only get worse, because of the severe of their disabilities

We therefore will be contacting Grunenthal shortly with the chance of opening discussions.



The Thalidomide UK is not responsible for the content of external Internet sites and remain Impartial to any legal challengers.


Nichola Marshall, Solicitor assisting Martyn Day

Leigh Day & Co. Priory House, 25 St John's Lane, London EC1M 4LB

Tel secretary: 020 7650 1234, Direct Dial, 0207 650 1324 Fax: 020 7253 4433

DX 53326 Clerkenwell

Description: Description: Description: Description: Description: Description: Leigh Day Logo


© Thalidomide UK 2002. All rights reserved